Document Type : Original Article

Authors

1 Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Mashhad, Iran

2 Department of Animal Science, Faculty of Agriculture, Shahid Bahonar University of Kerman, Kerman, Iran

Abstract

Newcastle disease virus (NDV) sub-genotype VII.1.1 is the most common circulating NDV in Iran. In this study, a velogenic NDV isolate was plaque purified and then characterized according to Office International des Epizooties (OIE) standard protocols. The biological properties of the purified isolate named CH/RT40/IR/2011 were characterized using sequencing and phylogenetic analysis, measurement of pathogenicity indexes and challenge studies. The isolate was plaque purified on chicken embryo fibroblast cells for three rounds and then characterized using molecular and biological approaches. Phylogenetic and evolutionary distance analysis of fusion and hemagglutinin-neuraminidase genes classified the virus in sub-genotype VII.1.1. No mutation was observed in the glycosylation and neutralizing epitope sites of the fusion and hemagglutinin-neuraminidase proteins compared to other reported Iranian NDV VII.1.1 isolates. The presence of the 112RRQKRF117 motif in the fusion protein cleavage site together with mean death time, intracerebral pathogenicity index and intravenous pathogenicity index of 57 hr, 1.80 and 2.50 respectively, revealed that the RT40 isolate was a velogenic NDV. In the challenge study, all chickens were inoculated via eye drop, and intranasal route with RT40 isolate died within a week. While all chickens in the vaccinated and challenged group survived and showed no clinical signs. In conclusion, according to genetic analysis, pathotyping and challenge study, the RT40 isolate was similar to virulent NDVs in Iran and was a suitable candidate for a national standard challenge strain, vaccine trials and vaccine production in commercial levers.

Keywords

  1. Dimitrov KM, Abolnik C, Afonso CL, et al. Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus. Infect Genet Evol 2019; 74: 103917. doi: 10.1016/j.meegid. 2019.103917.
  2. OIE, Manual of diagnostic tests and vaccines for terrestrial animals. 8th Paris, France: World Organization for Animal Health 2017.
  3. Miller PJ, Haddas R, Simanov L, et al. Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features. Infect Genet Evol 2015; 29: 216-229.
  4. Peeters B, Verbruggen P, Nelissen F, et al. The P gene of Newcastle disease virus does not encode an accessory X protein. J Gen Virol 2004; 85(Pt 8): 2375-2378.
  5. Suarez DL, Miller PJ, Koch G, et al. Newcastle disease, other avian paramyxoviruses, and avian meta-pneumovirus infections. In: Swayne DE, Glisson JR, McDougald LR, et al (Eds). Diseases of poultry. 13th Iowa, USA: Wiley-Blackwell 2013; 89-138.
  6. Heiden S, Grund C, Röder A, et al. Different regions of the Newcastle disease virus fusion protein modulate pathogenicity. PLoS One 2014; 9(12): e113344. doi: 10.1371/journal.pone.0113344.
  7. Liu J, Zhu J, Xu H, et al. Effects of the HN antigenic difference between the vaccine strain and the challenge strain of Newcastle disease virus on virus shedding and transmission. Viruses 2017; 9(8): 225. doi: 10.3390/v9080225.
  8. Molouki A, Mehrabadi MHF, Bashashati M, et al. NDV subgenotype VII (L) is currently circulating in commercial broiler farms of Iran 2017-2018. Trop Anim Health Prod 2019; 51(5): 1247-1252.
  9. Allahyari E, Allymehr M, Molouki A, et al. Molecular characterisation and phylogenetic study of the fusion gene of Newcastle disease viruses isolated from broiler farms of Iran in 2018-2019. Bulg J Vet Med 2022; 25(1): 21-32.
  10. Ahmadi E, Pourbakhsh SA, Ahmadi M, et al. Phylo-genetic characterization of virulent Newcastle disease viruses isolated during outbreaks in northwestern Iran in 2010. Arch Virol 2016; 161(11): 3151-3160.
  11. Dortmans JC, Peeters BP, Koch G Newcastle disease virus outbreaks: vaccine mismatch or inadequate application? Vet Microbiol 2012; 160(1-2): 17-22.
  12. Dimitrov KM, Afonso CL, Yu Q, et al. Newcastle disease vaccines-A solved problem or a continuous challenge? Vet Microbiol 2017; 206: 126-136.
  13. Miller PJ, Afonso CL, El Attrache J, et al. Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses. Dev Comp Immunol 2013; 41(4): 505-513.
  14. Toroghi, R. Isolation and nucleotide sequencing of the fusion protein gene cleavage site of Newcastle disease viruses contributing in respiratory syndromes of commercial chicken flocks in Khorasan Razavi province. Project report No 45939. Razi Vaccine and Serum Research Institute, Agricultural Research, Education, and Extension Organization, Iran 2014.
  15. Sambrook J, Russell DW, et al. The condensed protocols from molecular cloning: An laboratory manual. 1st Heidelberg, Germany: Heidelberg University Library 2006; 10-23.
  16. Umali DV, Ito H, Shirota K, et al. Characterization of complete genome sequence of genotype VI and VII velogenic Newcastle disease virus from Japan. Virus Genes 2014; 49(1): 89-99.
  17. Neyt C, Geliebter J, Slaoui M, et al. Mutations located on both F1 and F2 subunits of the Newcastle disease virus fusion protein confer resistance to neutralization with monoclonal antibodies. J Virol 1989; 63(2): 952-954.
  18. Yusoff K, Nesbit M, McCartney H, et al. Location of neutralizing epitopes on the fusion protein of Newcastle disease virus strain Beaudette C. J Gen Virol 1989; 70(Pt 11): 3105-3109.
  19. Ghalyanchilangeroudi A, Hosseini H, Jabbarifakhr M, et al. Emergence of a virulent genotype VIIi of Newcastle disease virus in Iran. Avian Pathol 2018; 47(5): 509-519.
  20. Toroghi R, Salamatian I, Bassami MR, et al. Implementation of high-level biosecurity measures can reduce the baseline antibody titers of Newcastle disease in non-integrated layer flocks in northeast Iran. Worlds Poult Sci J 2020; 76(4): 757-766.
  21. Bello MB, Mahamud SNA, Yusoff K, et al. Development of an effective and stable genotype-matched live attenuated Newcastle disease virus vaccine based on a novel naturally recombinant Malaysian isolate using reverse genetics. Vaccines 2020; 8: 270. doi:10.3390/ vaccines8020270.
  22. Zhou Y, McNamara RP, Dittmer DP. Purification methods and the presence of RNA in virus particles and extracellular vesicles. Viruses 2020; 12(9): 917. doi: 10.3390/v12090917.
  23. Théry C, Witwer K, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018; 7(1): 1535750. doi: 10.1080/20013078.2018.1535750.
  24. Sardjono B. Plaque assay of Newcastle disease virus. Bul Penelit Kesehat 1989; 17(2): 207-215.
  25. Schloer GM, Hanson RP. Relationship of plaque size and virulence for chickens of 14 representative Newcastle disease virus strains. J Virol 1968; 2(1): 40-47.
  26. Sabouri F, Vasfi Marandi M, Bashashati M. Characterization of a novel VIIl sub-genotype of Newcastle disease virus circulating in Iran. Avian Pathol 2018; 47(1): 90-99.
  27. Esmaelizad M, Mayahi V, Pashaei M, et al. Identification of novel Newcastle disease virus sub-genotype VII-(j) based on the fusion protein. Arch Virol 2017; 162(4): 971-978.
  28. Khan TA, Rue CA, Rehmani SF, et al. Phylogenetic and biological characterization of Newcastle disease virus isolates from Pakistan. J Clin Microbiol 2010; 48(5): 1892-1894.
  29. Wajid A, Dundon WG, Hussain T, et al. Pathotyping and genetic characterization of avian avulavirus-1 from domestic and wild waterfowl, geese and black swans in Pakistan, 2014 to 2017. Arch Virol 2018; 163(9): 2513-2518.
  30. Scanlon DB, Corino GL, Shiell BJ, et al. Pathotyping isolates of Newcastle disease virus using antipeptide antibodies to pathotype-specific regions of their fusion and hemagglutinin-neuraminidase proteins. Arch Virol 1999; 144(1): 55-72.
  31. Miller PJ, Estevez C, Yu Q, et al. Comparison of viral shedding following vaccination with inactivated and live Newcastle disease vaccines formulated with wild-type and recombinant viruses. Avian Dis 2009; 53(1): 39-49.
  32. Courtney SC, Susta L, Gomez D, et al. Highly divergent virulent isolates of Newcastle disease virus from the Dominican Republic are members of a new genotype that may have evolved unnoticed for over 2 decades. J Clin Microbiol 2013; 51(2): 508-517.
  33. Cardenas-Garcia S, Diel DG, Susta L, et al. Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines. Biologicals 2015; 43(2): 136-145.
  34. Kapczynski DR, King DJ. Protection of chickens against overt clinical disease and determination of viral shedding following vaccination with commercially available Newcastle disease virus vaccines upon challenge with highly virulent virus from the California 2002 exotic Newcastle disease outbreak. Vaccine 2005; 23(26): 3424-3433.